Jiangsu Gdk Biological Technology Co., Ltd (SHA:688670)
China
· Delayed Price · Currency is CNY 19.20
+0.45 (2.40%)
Mar 10, 2026, 3:00 PM CST
SHA:688670 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Operating Revenue | 113.23 | 80.8 | 134.59 | 318.49 | 390.56 | Upgrade
|
| Other Revenue | - | - | - | - | 1.71 | Upgrade
|
| Revenue | 113.23 | 80.8 | 134.59 | 318.49 | 392.27 | Upgrade
|
| Revenue Growth (YoY) | 40.13% | -39.96% | -57.74% | -18.81% | -33.41% | Upgrade
|
| Cost of Revenue | - | 51.87 | 86.29 | 87.41 | 114.52 | Upgrade
|
| Gross Profit | 113.23 | 28.93 | 48.3 | 231.07 | 277.75 | Upgrade
|
| Selling, General & Admin | - | 117.06 | 134.1 | 166.35 | 163.09 | Upgrade
|
| Research & Development | - | 33.61 | 15.47 | 32.41 | 35.26 | Upgrade
|
| Other Operating Expenses | 305.41 | 1.93 | 1.35 | 2.84 | 3.56 | Upgrade
|
| Operating Expenses | 305.41 | 155.27 | 139.66 | 202.75 | 203.18 | Upgrade
|
| Operating Income | -192.18 | -126.34 | -91.36 | 28.32 | 74.58 | Upgrade
|
| Interest Expense | - | -1.6 | -1.9 | -1.28 | -9.85 | Upgrade
|
| Interest & Investment Income | - | 13.04 | 15.15 | 17.53 | 7.69 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | 0 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0.16 | -3.81 | -0.9 | -0.02 | -0.01 | Upgrade
|
| EBT Excluding Unusual Items | -192.01 | -118.71 | -79.01 | 44.55 | 72.4 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 0.17 | -0.15 | -1.74 | 2.31 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.1 | - | 0.23 | -0.05 | Upgrade
|
| Asset Writedown | - | -0.88 | -0.24 | -3.29 | -3.75 | Upgrade
|
| Other Unusual Items | - | 3.77 | -7.18 | 8.66 | 13.09 | Upgrade
|
| Pretax Income | -192.01 | -115.75 | -86.57 | 48.41 | 84 | Upgrade
|
| Income Tax Expense | -18.54 | -22.25 | -15.58 | 6.86 | 1.54 | Upgrade
|
| Net Income | -173.47 | -93.5 | -70.99 | 41.54 | 82.46 | Upgrade
|
| Net Income to Common | -173.47 | -93.5 | -70.99 | 41.54 | 82.46 | Upgrade
|
| Net Income Growth | - | - | - | -49.62% | -46.79% | Upgrade
|
| Shares Outstanding (Basic) | 123 | 123 | 122 | 122 | 105 | Upgrade
|
| Shares Outstanding (Diluted) | 123 | 123 | 122 | 122 | 105 | Upgrade
|
| Shares Change (YoY) | 0.00% | 0.52% | 0.17% | 16.43% | 13.67% | Upgrade
|
| EPS (Basic) | -1.41 | -0.76 | -0.58 | 0.34 | 0.79 | Upgrade
|
| EPS (Diluted) | -1.41 | -0.76 | -0.58 | 0.34 | 0.79 | Upgrade
|
| EPS Growth | - | - | - | -56.73% | -53.19% | Upgrade
|
| Free Cash Flow | - | -169.86 | 26.9 | -129.58 | -282.46 | Upgrade
|
| Free Cash Flow Per Share | - | -1.38 | 0.22 | -1.06 | -2.69 | Upgrade
|
| Dividend Per Share | - | - | - | 0.143 | 0.357 | Upgrade
|
| Dividend Growth | - | - | - | -59.98% | - | Upgrade
|
| Gross Margin | 100.00% | 35.80% | 35.89% | 72.55% | 70.81% | Upgrade
|
| Operating Margin | -169.72% | -156.35% | -67.88% | 8.89% | 19.01% | Upgrade
|
| Profit Margin | -153.20% | -115.72% | -52.74% | 13.04% | 21.02% | Upgrade
|
| Free Cash Flow Margin | - | -210.22% | 19.99% | -40.69% | -72.01% | Upgrade
|
| EBITDA | -163.36 | -97.52 | -61.49 | 58.08 | 102.65 | Upgrade
|
| EBITDA Margin | -144.27% | -120.69% | -45.68% | 18.24% | 26.17% | Upgrade
|
| D&A For EBITDA | 28.82 | 28.82 | 29.87 | 29.76 | 28.08 | Upgrade
|
| EBIT | -192.18 | -126.34 | -91.36 | 28.32 | 74.58 | Upgrade
|
| EBIT Margin | -169.72% | -156.35% | -67.88% | 8.89% | 19.01% | Upgrade
|
| Effective Tax Rate | - | - | - | 14.18% | 1.83% | Upgrade
|
| Revenue as Reported | - | 80.8 | 134.59 | 318.49 | 392.27 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.